Literature DB >> 28915685

Prognostic significance of neutrophil-to-lymphocyte ratio in patients with malignant pleural mesothelioma: a meta-analysis.

Nan Chen1, Shuai Liu1, Lin Huang1, Wanling Li1, Wenhao Yang1, Tianxin Cong1, Lin Ding1, Meng Qiu1,2.   

Abstract

Systemic inflammation responses can be reflected by peripheral blood count and combine index like the neutrophil-to-lymphocyte (NLR). The NLR has been reported to be a poor prognostic indicator in cancer recently. However, the prognostic effect of the NLR in patients with malignant pleural mesothelioma (MPM) still unclear yet. We conducted this meta-analysis aiming to evaluate the pooled value of NLR in prognosis as well as clinical characteristics in malignant pleural mesothelioma. A total of 11 studies with 1533 patients were included in this meta-analysis, in which 10 studies investigated the prognosis role of NLR using hazard ratio (HR) and 95% confidence intervals (95% CI). The elevated NLR was detected to be associated with a poor overall survival (OS)(HR=1.48, 95%CI=1.16-1.89, P < 0.001). The significant prognostic roles of NLR were also indicated in subgroup analyses. NLR level was also associated with histology instead of gender, stage or performance status (PS) score. These findings suggested that the elevated NLR could be a potential prognostic factor for malignant pleural mesothelioma patients and might be associated with histology as an efficient clinical index to stratify patients.

Entities:  

Keywords:  inflammation; malignant pleural mesothelioma; meta-analysis; neutrophil-to-lymphocyte ratio; prognosis

Year:  2017        PMID: 28915685      PMCID: PMC5593657          DOI: 10.18632/oncotarget.15404

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


INTRODUCTION

Malignant pleural mesothelioma (MPM) is a high aggressive tumor originates from mesothelial surfaces with a poor prognosis and a median survival of 9 to 13 months [1], and there were still no reliable prognostic indicators. Several prognostic biomarkers have been reported in the literature which including hemoglobin and white blood cell counts, performance status according to the Eastern Cooperative Oncology Group (ECOG) scale, age, weight loss, disease stage and imaging results (tumor volume, metabolic activity) to distinguish patients with good prognosis from those with inferior outcomes [2, 3]. Although these results for the prognosis helpful, but they were far from enough to predict the survival outcomes. Therefore, studies to further identify novel prognostic factors associated with accuracy and efficiency calls for the exertion of clinicians. Inflammatatory responses have been found associated with tumor progression, evidence also shown that increased systemic inflammation was associated with poor overall survival (OS) in numerous types of cancer [4-9]. Inflammation is a crucial component of tumor microenvironment [8]. Inflammatory cells in the tumor microenvironment have important effects on tumor development, and markers of systemic inflammation may provide significant information for prognostication. Accumulating evidence suggested inflammation-related cells correlated closely with cancer are including neutrophils [10, 11], platelets [12], and lymphocytes [13]. Neutrophil to lymphocyte ratio (NLR), calculated as a simple ratio between neutrophil and lymphocyte counts, an index of systemic inflammation, has been related to poor survival for a variety of malignant tumors as renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, prostate cancer and gastric cancer [14-18]. Therefore, it is a reasonable assumption that these two factors together might be applied as a prognostic factor. Here, we conducted a meta-analysis aiming to further verify the pooled prognostic value of NLR in malignant pleural mesothelioma.

RESULTS

Study characteristics and qualities

The flow chart of selection process was shown in Figure 1. We initially retrieved 380 studies in total without duplicates. After further screening, 365 studies were excluded for conference abstracts, case reports, reviews, or studies unrelated to this meta-analysis. Then, 15 studies were identified for the next step of evaluation with full text. During the further analysis, 4 studies [19, 20, 21, 22] were ruled out because they were failed to present specific NLR data for OS, not available in neither univariate nor multivariate analysis, or failed to estimate via sufficient information for HR and 95%CI, or studies with overlapping patients. Thus, finally 11 studies with 1533 patients were included in our meta-analysis, in which 10 studies [23-32] valuated the association between NLR and survival of malignant pleural mesothelioma patients, four study [23, 27, 29, 31] were included for investigation of NLR and patients’ clinical characteristics. The publication time ranged from 2010 to 2016. The ethnicities of the studies contained Asian and Caucasian. We extracted HR and 95%CI from multivariate analysis in seven studies and univariate analysis in three studies. All included studies reported data for OS. The study quality was evaluated via Newcastle-Ottawa scale, and the scores of the 11 studies ranged from 6 to 8. The main characteristics were shown in Table 1.
Figure 1

The flow chart of study selection

NLR: neutrophil-to-lymphocyte; OS: overall survival; HR: hazard ratio; CI: confidence intervals.

Table 1

The baseline characteristics of included studies

AuthorYearCountryEthnicityNaStudy designStageTreatmentCut-off valueAnalysisNOS score
Abakay2014TurkeyCaucasian155RetrospectiveNANA3NA8
Cedres2014SpainCaucasian52RetrospectiveIII/IVChemotherapy/best supportive care5MV6
Cihan2014TurkeyCaucasian50RetrospectiveI/II/III/IVSurgery/Chemotherapy/Radiotherapy3UV6
Hooper2015the UKCaucasian73ProspectiveI/II/III/IVChemotherapy/best supportive care4MV8
Kao2013AustraliaCaucasian148RetrospectiveI/II/III/IVSurgery/Chemotherapy/Radiotherapy3MV6
Kao2011AustraliaCaucasian85RetrospectiveI/II/III/IVSurgery/neoadjuvant chemotherapy3MV7
Kao2010AustraliaCaucasian173RetrospectiveI/II/III/IVFirst-line/second/third-line chemotherapy5MV8
Meniawy2013AustraliaCaucasian274RetrospectiveI/II/III/IVSurgery/Chemotherapy/best supportive care5MV7
Pinato2012the UKCaucasian171RetrospectiveI/II/III/IVChemotherapy/best supportive care5MV8
Tanrikulu2015TurkeyCaucasian202RetrospectiveI/II/III/IVChemotherapy/best supportive care3MV6
Yamagishi2015JapanAsian150RetrospectiveI/II/III/IVSurgery/Chemotherapy/Radiotherapy/best supportive care5UV6

a Number of included patients

NA: not available; OS: overall survival; MV: multivariate analysis; UV: univariate analysis; NOS: Newcastle-Ottawa Quality Assessment Scale.

The flow chart of study selection

NLR: neutrophil-to-lymphocyte; OS: overall survival; HR: hazard ratio; CI: confidence intervals. a Number of included patients NA: not available; OS: overall survival; MV: multivariate analysis; UV: univariate analysis; NOS: Newcastle-Ottawa Quality Assessment Scale.

NLR and survival

There were 7 studies with multivariate analysis and 3 studies with univariate analysis providing information regarding OS. Overall, an elevated NLR was significantly associated with a poor OS (HR=1.48, 95%CI=1.16-1.89, P=0.001)(Figure 2). The significance was detected in studies with multivariate analysis (HR=1.50, 95%CI=1.15-1.95, P=0.003). We further detected a significant association between NLR and OS in studies with Caucasian population (HR=1.44, 95%CI=1.11-1.86, P=0.006), larger sample size (HR=1.58, 95%CI=1.07-2.35, P=0.022), higher study quality (HR = 1.579, 95%CI=1.12-2.22, P=0.009) and cut-off value of five (HR=1.68, 95%CI=1.10-2.56, P=0.015). The detailed results were shown in Table 2 and the extracted data were presented in Supplementary table S1.
Figure 2

Forest plot of the association between NLR and OS in MPM overallly

The elevated NLR was detected to be significantly associated with a poor OS. HR: hazard ratio; CI: confidence intervals.

Table 2

The pooled data on survival of meta-analysis

VariablesNaCasebPooled dataHeterogeneity
HR(95%CI)PI2Ph
Overall1013781.483(1.164-1.889)0.00178.3%<0.001
Ethnicity
Caucasian912281.437(1.112-1.857)0.00678.6%<0.001
Asian11501.930(1.278-2.915)0.002NANA
Study design
Retrospective913051.537(1.138-2.076)0.00575.5%<0.001
Prospective1731.170(1.065-1.286)0.001NANA
Survival analysis
Multivariate811781.499(1.151-1.953)0.00380.4%<0.001
Univariate22001.261(0.473-3.362)0.64475.4%0.044
Sample size
≤14954081.368(0.948-1.973)0.09462.2%0.032
>14959701.583(1.067-2.349)0.02284.6%<0.001
Cut-off value
344851.358(0.844-2.185)0.20771.9%0.014
41731.170(1.065-1.286)0.001NANA
558201.681(1.104-2.560)0.01579.5%0.001
NOS score
≤656021.343(0.866-2.082)0.18869.5%0.011
>657761.579(1.123-2.221)0.00985.6%<0.001

a Numbers of studies included in the meta-analysis

b Number of patients of included studies

NA: not available; OS: overall survival; HR: hazard ratio; 95%CI: confidence interval; P: p value of pooled HR; I2: value of Higgins I-squared statistics; Ph: p value of Heterogeneity test.

Forest plot of the association between NLR and OS in MPM overallly

The elevated NLR was detected to be significantly associated with a poor OS. HR: hazard ratio; CI: confidence intervals. a Numbers of studies included in the meta-analysis b Number of patients of included studies NA: not available; OS: overall survival; HR: hazard ratio; 95%CI: confidence interval; P: p value of pooled HR; I2: value of Higgins I-squared statistics; Ph: p value of Heterogeneity test.

NLR and clinical characteristics

As for clinical characteristics, we detected NLR level was associated with histology (odds ratio (OR)=0.59, 95%CI=0.40-0.86, P=0.005), patients with non-epithelioid histological subtype are more likely in an elevated NLR. However, we failed to observe the association between NLR level with gender, tumor stage and performance status (PS) score. These results were presented in Table 3 and detailed extracted data were shown in Supplementary table S2.
Table 3

The pooled data on clinical characteristics of included studies

VariablesNaCasebPooled dataHeterogeneity
OR(95%CI)PI2Ph
Gender3488
MaleReference
Female0.793(0.516-1.219)0.2900.0%0.369
Histology4526
EpithelialReference
Non-epithelial0.588(0.404-0.855)0.00537.3%0.188
Stage2205
I/IIReference
III/IV0.677(0.342-1.339)0.2620.0%0.521
PS score2302
0Reference
≧10.652(0.379-1.120)0.1210.0%0.410

a Numbers of studies included in the meta-analysis

b Number of patients of included studies

PS score: performance status score; OR: odds ratio; 95%CI: confidence interval; P: p value of pooled HR; I2: value of X2 based I-squared statistics; Ph: p value of Heterogeneity test.

a Numbers of studies included in the meta-analysis b Number of patients of included studies PS score: performance status score; OR: odds ratio; 95%CI: confidence interval; P: p value of pooled HR; I2: value of X2 based I-squared statistics; Ph: p value of Heterogeneity test.

Sensitivity analysis and publication bias

Sensitivity analysis was performed and we did not observe any variations of the results, which proved the stability of results of our meta-analysis (Figure 3). In addition, The Begg's funnel plot (Pr>|z|=0.474) (Figure 4a) and the Egger's test (P>|t|=0.237) (Figure 4b) did not detected any evidence of publication bias for OS, as well as for clinical characteristics.
Figure 3

Sensitivity analysis of included studies to evaluate the stability of our results

We did not observe any variations of the results, which proved the stability of results of our meta-analysis.

Figure 4

Begg's funnel plot (a) and Egger's linear regression tests (b) for the assessment of potential publication bias

We did not detected any evidence of publication bias for OS.

Sensitivity analysis of included studies to evaluate the stability of our results

We did not observe any variations of the results, which proved the stability of results of our meta-analysis.

Begg's funnel plot (a) and Egger's linear regression tests (b) for the assessment of potential publication bias

We did not detected any evidence of publication bias for OS.

DISCUSSION

Systemic inflammatory response is important in cancer progresssion [33]. Inflammation-relatated cells involved in the constitution and regulation of tumer cell microenvironment. It may act as an intermediary between tumor cell and inflammatory. Different peripheral blood count may reflect the body's inflammatory response, and NLR as an combined index may reflect the balance between neutrophils and immunocytes, making it a prognostic factor. Several studies have demonstrated that elevated NLR is related with a poor prognosis in MPM, but the result still controversial. Thus we conducted this meta-analysis and it was the first to indicate that a high NLR was associated with poor survival of patients with MPM. Similar to our study, a recent clinical research published in 2016 investigated the relation between NLR and malignant pleural mesothelioma [22]. In their research they collected and analysised 36 patients’ clinical information, and didn't detect any significant correlation bettwen NLR and MPM prognosis. Thus we could find that NLR on prognosis of patients with malignant pleural mesothelioma was still a question worth exploring. These studies just as we mentioned above, might not be able to draw reliable conclusions with the limitation of sample size. Our research using the method of meta-analysis contained a larger sample size, and might be more credible and provide more reliable information compared to other single clinical research. Base on the result of our meta-analysis, we found that an elevated NLR was significantly associated with a poor OS. Furthermore, results were proved in subgroup analysis stratified by ethnicity, study design, suvival analysis, cut-off value and NOS score. In addition, relationship between NLR and clinical characters including histology, gender, tomur stageand performance status (PS) score were also accessed. NLR level was associated with histology of malignant pleural mesothelioma that it was higher in patients with a nonepithelioid histological subtype. However, we failed to detected any association between NLR level with gender, tumor stage and performance status (PS) score. Our study were in correspondence with previous studies which investigated the prognosis value of NLR in other kind of tumors such as liver cancer [34], colorectal cancer [35], pancreatic cancer [36], etc. These study also demonstrated that an elevated NLR was important in predicting prognosis before treatment. Thus it was believed to be a promising marker playing role in cancer diagnosis, prognosis prediction and individual treatment in future. However, the optimal cut-off value for NLR in predicting the prognosis of gastric cancer remains unclear [37]. The cut-off values in our analysis ranged from 3 to 5, and they were determined by the median value of all patients, or on the basis of previous studies. To establish a suitable cut-off value, we performed subgroup analyses with the cut-off values. Most included studies applied five as cut-off value and significant survival outcomes were detected in subgroup stratified patients by five. Our results were not consistent with some published studies, we didn't find the association between NLR level and tumor stage. A possible explanation for this might be that the degree of inflamation is different from patients in different tumor stage. Several studies had shown that malignant pleural tumors were always secondary to asbestosis exposion, and early pleural tumors were more easily associated with acute infection and inflammation effusion. By contrast, the chance of acute inflammatory response in advanced pleural tumor patients is less. Unfortunately, patients with the presence of active infection were more likely to be excluded from the study in patients selection process, which may lead to a negative result. More studies were warranted on this filed in future. Our study has some limitations. First, although we made comprehensive search, there were only 11 studies included and the limited patients numbers may have influence on the outcomes, thus futher studies at a large scale might be needed to confirm the prognosis value of NLR in MPM. In addiation, heterogeneity was a potential problem that may reduce the accurary of the results. Difference in baseline features of included studies such as histology, treatment, cut-off value of NLR and follow-up period, etc might potentially have influence in pooled results. Finally, some original articles evaluated the prognostic effect of NLR in univariate analysis, whereas others had data of multivariate analysis, which may contribute to some bias of the pooled data. In conclusion, our study demonstrated that the elevated NLR predicted poor survival of MPM. And NLR also might be associated with histology of MPM. The NLR could be useful for predicting survival of patients with MPM. Further studies were warranted to conform the exact value of NLR in the prognosis of MPM.

MATERIALS AND METHODS

Search strategy

A systemic search was conducted in PubMed, Embase and web of Science databases update to Jun 26, 2016. The following words were applied as search terms: “neutrophil-to-lymphocyte”, “neutrophil-lymphocyte ratio”, “neutrophil/lymphocyte ratio”, “NLR”, “malignant pleural mesothelioma”, “malignant mesothelioma”, “pleural mesothelioma”, “MPM”, “MM”. There was no language restriction of our literature search. The references of identified articles were retrieved manually for potential eligible studies.

Inclusion and exclusion criteria

Studies met the following criteria were considered eligible: (1) the studies investigated the association between NLR and prognosis or clinical characteristics of MPM patients; (2) for prognosis, hazard ratio (HR) and 95% CI were reported, or Kaplan-Meier curve and relevant information were available to estimate HR and 95% CI. (3) for clinical characteristics, odds ratio (OR) and 95% CI were used to measure the association. We excluded studies if they: (1) were conference abstracts, letters, case reports; (2) failed to report failed to present specific NLR data for OS in neither univariate nor multivariate analysis, or failed to estimate via sufficient information for HR and 95%CI, or NLR as a continue variable; (3) presented to be duplicate publications. When studies with overlapping patients were met, only the study with the most patients was included. Two investigators (Nan Chen and Shuai Liu) reviewed the identified studies independently and a final discussion was launched to reach a consistency.

Data extraction and quality assessment

Two investigators(Nan Chen and Lin Huang) extracted information independently using a standard data extraction table. The following information were recorded for each included study: name of first author, year of publication, ethnicity, number of recruited patients, treatment of patient, follow-up time, analysis method, type of survival, cut-off value for NLR, clinical characteristics information, HR and 95% CI for survival. The Newcastle-Ottawa Quality Assessment Scale (NOS) was used to assess the quality of each included study independently by these two investigators. NOS score more than 6 were considered as high-quality studies. The two investigators discussed to reach a consensus when there was any disagreement. The Newcastle-Ottawa Quality Assessment Scale (NOS) we used was shown in Supplementary table S3 and the detailed scores of each included study was presented in Supplementary table S4.

Statistics analysis

In this meta-analysis, OR with 95%CI was used to evaluate the association between NLR and clinical characteristics. As for prognosis, HR and 95%CI were extracted from each study to calculate the pooled HR (high level vs. low level). When the study reported both univariate and multivariate results, we chose multivariate analysis for final calculation. While the HR and 95%CI were not reported directly, Kaplan-Meier curve and relevant data were collected to estimate related HR with 95%CI. Test of heterogeneity was conducted by Cochran's Q test and Higgins I-squared statistic. P>0.10 and I2<50% were regarded as no significant heterogeneity and the fixed-effects model was used. Otherwise, the random-effects model was applied. In addition, further subgroup analyses to explore potential heterogeneity were performed stratified by ethnicity, sample size, study design, survival analysis, NOS score and cut-off value. We further conducted sensitivity to evaluate the stability of the results. Additionally, Begg's funnel plot and Egger's linear regression tests were performed to access publication bias. All the analyses were carried out by STATA 12.0 (STATA Corporation, College Station, TX, USA).
  37 in total

1.  Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume.

Authors:  Ritu R Gill; William G Richards; Beow Y Yeap; Shin Matsuoka; Andrea S Wolf; Victor H Gerbaudo; Raphael Bueno; David J Sugarbaker; Hiroto Hatabu
Journal:  AJR Am J Roentgenol       Date:  2012-02       Impact factor: 3.959

2.  Health-related quality of life and inflammatory markers in malignant pleural mesothelioma.

Authors:  Steven C Kao; Janette Vardy; Rozelle Harvie; Mark Chatfield; Nico van Zandwijk; Stephen Clarke; Nick Pavlakis
Journal:  Support Care Cancer       Date:  2012-08-31       Impact factor: 3.603

3.  High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy.

Authors:  Steven C H Kao; Nick Pavlakis; Rozelle Harvie; Janette L Vardy; Michael J Boyer; Nico van Zandwijk; Stephen J Clarke
Journal:  Clin Cancer Res       Date:  2010-10-18       Impact factor: 12.531

4.  Expression of Wilms' tumor gene (WT1) is associated with survival in malignant pleural mesothelioma.

Authors:  S Cedrés; M A Montero; E Zamora; A Martínez; P Martínez; L Fariñas; A Navarro; D Torrejon; A Gabaldon; S Ramon Y Cajal; E Felip
Journal:  Clin Transl Oncol       Date:  2013-12-10       Impact factor: 3.405

Review 5.  Cancer-related inflammation.

Authors:  Juliana Candido; Thorsten Hagemann
Journal:  J Clin Immunol       Date:  2012-12-09       Impact factor: 8.317

6.  Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.

Authors:  B Ghanim; T Klikovits; M A Hoda; G Lang; I Szirtes; U Setinek; A Rozsas; F Renyi-Vamos; V Laszlo; M Grusch; M Filipits; A Scheed; M Jakopovic; M Samarzija; L Brcic; D Stancic-Rokotov; I Kern; A Rozman; G Dekan; W Klepetko; W Berger; T Glasz; B Dome; B Hegedus
Journal:  Br J Cancer       Date:  2015-01-29       Impact factor: 7.640

Review 7.  Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients.

Authors:  Xiaobin Gu; Xianshu Gao; Xiaoying Li; Xin Qi; Mingwei Ma; Shangbin Qin; Hao Yu; Shaoqian Sun; Dong Zhou; Wen Wang
Journal:  Sci Rep       Date:  2016-02-25       Impact factor: 4.379

8.  Loss of SHP-2 activity in CD4+ T cells promotes melanoma progression and metastasis.

Authors:  Tao Zhang; Wenjie Guo; Yang Yang; Wen Liu; Lele Guo; Yanhong Gu; Yongqian Shu; Lu Wang; Xuefeng Wu; Zichun Hua; Yuehai Ke; Yang Sun; Yan Shen; Qiang Xu
Journal:  Sci Rep       Date:  2013-10-03       Impact factor: 4.379

9.  Epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma and pancreatic tumor cell lines: the role of neutrophils and neutrophil-derived elastase.

Authors:  Thomas Grosse-Steffen; Thomas Giese; Nathalia Giese; Thomas Longerich; Peter Schirmacher; G Maria Hänsch; Matthias M Gaida
Journal:  Clin Dev Immunol       Date:  2012-11-20

10.  Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio reliable parameters as prognostic indicators in malignant mesothelioma?

Authors:  Seda Tural Onur; Sinem Nedime Sokucu; Levent Dalar; Sinem Iliaz; Kaan Kara; Songül Buyukkale; Sedat Altin
Journal:  Ther Clin Risk Manag       Date:  2016-04-22       Impact factor: 2.423

View more
  10 in total

1.  Neutrophil to Lymphocyte Ratio as Predictor of Treatment Response in Esophageal Squamous Cell Cancer.

Authors:  Arianna Barbetta; Tamar B Nobel; Smita Sihag; Meier Hsu; Kay See Tan; Manjit S Bains; James M Isbell; Yelena Y Janjigian; Abraham J Wu; Matthew J Bott; David R Jones; Daniela Molena
Journal:  Ann Thorac Surg       Date:  2018-05-05       Impact factor: 4.330

2.  Biomarkers in malignant pleural mesothelioma: current status and future directions.

Authors:  Tamkin Ahmadzada; Glen Reid; Steven Kao
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

Review 3.  Progress in the Management of Malignant Pleural Mesothelioma in 2017.

Authors:  Amanda J McCambridge; Andrea Napolitano; Aaron S Mansfield; Dean A Fennell; Yoshitaka Sekido; Anna K Nowak; Thanyanan Reungwetwattana; Weimin Mao; Harvey I Pass; Michele Carbone; Haining Yang; Tobias Peikert
Journal:  J Thorac Oncol       Date:  2018-03-08       Impact factor: 15.609

4.  Prognostic Impact of Inflammation-related Biomarkers on Overall Survival of Patients with Inoperable Malignant Pleural Mesothelioma.

Authors:  Takehiro Otoshi; Yuki Kataoka; Sawako Kaku; Reika Iki; Masataka Hirabayashi
Journal:  In Vivo       Date:  2018 Mar-Apr       Impact factor: 2.155

5.  The prognostic values of neutrophil to lymphocyte ratio for outcomes in chronic obstructive pulmonary disease.

Authors:  Zengpanpan Ye; Xiaolin Ai; Zenglin Liao; Chao You; Yongzhong Cheng
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

6.  Ki67 (MIB-1) as a Prognostic Marker for Clinical Decision Making Before Extended Pleurectomy Decortication in Malignant Pleural Mesothelioma.

Authors:  Robert A Belderbos; Alexander P W M Maat; Sara J Baart; Eva V E Madsen; Ad J J C Bogers; Robin Cornelissen; Joachim G J V Aerts; Edris A F Mahtab; Jan H von der Thüsen
Journal:  JTO Clin Res Rep       Date:  2021-02-15

7.  Sarcopenia as a Predictor of Short- and Long-Term Outcomes in Patients Surgically Treated for Malignant Pleural Mesothelioma.

Authors:  Eleonora Faccioli; Stefano Terzi; Chiara Giraudo; Andrea Zuin; Antonella Modugno; Francesco Labella; Giovanni Zambello; Giulia Lorenzoni; Marco Schiavon; Dario Gregori; Giulia Pasello; Fiorella Calabrese; Andrea Dell'Amore; Federico Rea
Journal:  Cancers (Basel)       Date:  2022-07-29       Impact factor: 6.575

8.  Predictive value of inflammation-based prognostic scores in patients with metastatic renal cell carcinoma treated with cytoreductive nephrectomy.

Authors:  Hironori Fukuda; Toshio Takagi; Tsunenori Kondo; Satoru Shimizu; Kazunari Tanabe
Journal:  Oncotarget       Date:  2018-02-16

Review 9.  Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade.

Authors:  Youhai Jiang; Xiaofang Zhao; Jing Fu; Hongyang Wang
Journal:  Front Immunol       Date:  2020-03-12       Impact factor: 7.561

10.  Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies.

Authors:  Meghan A Cupp; Margarita Cariolou; Ioanna Tzoulaki; Dagfinn Aune; Evangelos Evangelou; Antonio J Berlanga-Taylor
Journal:  BMC Med       Date:  2020-11-20       Impact factor: 8.775

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.